Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03818581 · ClinicalTrials.gov registry record · Phase 4
Suvorexant on Sleep Disturbance in Patients With Chronic Insomnia and Suboptimally Controlled Type 2 Diabetes
A Phase 4 study of Insomnia and Inflammation, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 108
- Enrollment target
- 1
- Study location
NCT03818581 is a Phase 4 study of Insomnia and Inflammation that has completed, run by Massachusetts General Hospital. The registered enrollment target is 108 participants, below the 169-participant average among 151 other Insomnia trials with a reported enrollment target (36% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03818581, a Phase 4 study of Insomnia and Inflammation, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 108 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators aim to determine the effect of suvorexant on subjective total sleep time (TST) in suboptimally controlled Type 2 diabetics with chronic insomnia in a randomized placebo-controlled trial for 3 months.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Suvorexant
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2019-03-15 |
| Est. Completion | 2021-11-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03818581
The ClinicalTrials.gov registry entry for NCT03818581 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 169-participant average among 151 other Insomnia trials with a reported enrollment target (36% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Insomnia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03818581 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03818581 about?
NCT03818581 is a clinical study titled "Suvorexant on Sleep Disturbance in Patients With Chronic Insomnia and Suboptimally Controlled Type 2 Diabetes". The investigators aim to determine the effect of suvorexant on subjective total sleep time (TST) in suboptimally controlled Type 2 diabetics with chronic insomnia in a randomized placebo-controlled trial for 3 months.
What is the current status of trial NCT03818581?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 108 participants. The study started on 2019-03-15. Estimated completion is 2021-11-03.
What conditions does trial NCT03818581 study?
This clinical trial studies the following conditions: Insomnia, Inflammation, Type 2 Diabetes Mellitus, Sleep Disorder.
What interventions are being tested in trial NCT03818581?
The interventions under investigation include: Placebo (OTHER), Suvorexant (DRUG).
Who is sponsoring clinical trial NCT03818581?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03818581 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Insomnia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Comparing Digital Therapy, Trazodone, and Daridorexant for Menopause-Related Insomnia Symptoms
RECRUITING · Phase 4
-
Enhancing Hypnotic Medication Discontinuation in Primary Care
RECRUITING · Phase 4
-
Efficacy of Suvorexant in the Treatment of Insomnia in Midlife Women With Pre-Diabetes
RECRUITING · Phase 4
-
Evaluation of a Neurostimulation Device for Insomnia: A Randomized Trial
ACTIVE NOT RECRUITING · Phase 4
-
Solriamfetol and CBT-I in Patients With Insomnia Disorder
ACTIVE NOT RECRUITING · Phase 4
-
A Pilot Study of Suvorexant for Insomnia in Parkinson Disease
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.